Dynavax Technologies (DVAX) Announces Quarterly Earnings
Dynavax Technologies (NASDAQ: DVAX) released its earnings data on Friday. The company reported ($0.11) earnings per share for the quarter. The company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $11.40 million.
A number of research firms have also recently commented on DVAX. Analysts at McNicoll Lewis & Vlak downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note to investors on Monday. On a related note, analysts at MLV Capital downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note to investors on Monday. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Dynavax Technologies in a research note to investors on Thursday, February 21st. They now have a $5.00 price target on the stock.
Shares of Dynavax Technologies (DVAX) traded down 2.94% during mid-day trading on Friday, hitting $1.98. Dynavax Technologies (DVAX) has a one year low of $1.87 and a one year high of $5.34. The stock’s 50-day moving average is currently $2.97. The company’s market cap is $353.8 million.
Dynavax Technologies Corporation (Dynavax) is a biopharmaceutical company that discovers and develops products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.